Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ENZN's Cash to Debt is ranked higher than
99% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. ENZN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ENZN' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 2.06 Max: No Debt
Current: No Debt
Equity to Asset 0.99
ENZN's Equity to Asset is ranked higher than
100% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ENZN: 0.99 )
Ranked among companies with meaningful Equity to Asset only.
ENZN' s Equity to Asset Range Over the Past 10 Years
Min: -0.25  Med: 0.54 Max: 0.99
Current: 0.99
-0.25
0.99
Interest Coverage No Debt
ENZN's Interest Coverage is ranked higher than
99% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZN' s Interest Coverage Range Over the Past 10 Years
Min: 0.05  Med: 5.21 Max: 9999.99
Current: No Debt
0.05
9999.99
F-Score: 4
Z-Score: 37.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 56.06
ENZN's Operating margin (%) is ranked higher than
97% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. ENZN: 56.06 )
Ranked among companies with meaningful Operating margin (%) only.
ENZN' s Operating margin (%) Range Over the Past 10 Years
Min: -34.23  Med: 3.61 Max: 92.36
Current: 56.06
-34.23
92.36
Net-margin (%) 103.37
ENZN's Net-margin (%) is ranked higher than
98% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. ENZN: 103.37 )
Ranked among companies with meaningful Net-margin (%) only.
ENZN' s Net-margin (%) Range Over the Past 10 Years
Min: -43.19  Med: 28.12 Max: 181.11
Current: 103.37
-43.19
181.11
ROE (%) 72.93
ENZN's ROE (%) is ranked higher than
99% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. ENZN: 72.93 )
Ranked among companies with meaningful ROE (%) only.
ENZN' s ROE (%) Range Over the Past 10 Years
Min: -7.85  Med: 28.98 Max: 165.21
Current: 72.93
-7.85
165.21
ROA (%) 55.77
ENZN's ROA (%) is ranked higher than
99% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. ENZN: 55.77 )
Ranked among companies with meaningful ROA (%) only.
ENZN' s ROA (%) Range Over the Past 10 Years
Min: -4.99  Med: 10.79 Max: 136.6
Current: 55.77
-4.99
136.6
Revenue Growth (3Y)(%) -24.30
ENZN's Revenue Growth (3Y)(%) is ranked lower than
75% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ENZN: -24.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENZN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.7  Med: -3.40 Max: 96
Current: -24.3
-40.7
96
EBITDA Growth (3Y)(%) 62.40
ENZN's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ENZN: 62.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ENZN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.3  Med: -5.75 Max: 62.4
Current: 62.4
-55.3
62.4
» ENZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ENZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CSBR, NAS:ZSAN, OTCPK:BNHLF, OTCPK:GBLX, NAS:JAGX, OTCPK:QBIO, NAS:ACST, OTCPK:OPNT, OTCPK:BITRF, OTCBB:DDRT, NAS:RXII, OTCPK:MBXBF, NAS:BSTG, NAS:CBIO, NAS:MATN, AMEX:IMUC, NAS:WINT, OTCPK:ETST, NAS:XTLB, NAS:CYCC » details
Traded in other countries:EZ1.Germany,
Enzon Pharmaceuticals Inc is related to sales of drugs by various companies. It generates revenues from the sales of products namely, PegIntron, Sylatron, Macugen and CIMZIA.

Enzon Pharmaceuticals Inc is a biotechnology company. The Company is related to sales of six marketed drug products namely, PegIntron, Sylatron, Macugen, CIMZIA, Oncaspar and Adagen. The Company generates revenues from the royalty from the sales of PegIntron marketed by Merck & Co., Inc. The Company has a strategic alliance with Zhejiang Hisun Pharmaceuticals Co. Ltd development and commercialization rights for PEG-SN38 in China.

Ratios

vs
industry
vs
history
P/E(ttm) 1.11
ENZN's P/E(ttm) is ranked higher than
98% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. ENZN: 1.11 )
Ranked among companies with meaningful P/E(ttm) only.
ENZN' s P/E(ttm) Range Over the Past 10 Years
Min: 0.85  Med: 4.24 Max: 606.11
Current: 1.11
0.85
606.11
PE(NRI) 1.11
ENZN's PE(NRI) is ranked higher than
98% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. ENZN: 1.11 )
Ranked among companies with meaningful PE(NRI) only.
ENZN' s PE(NRI) Range Over the Past 10 Years
Min: 0.86  Med: 2.49 Max: 25.38
Current: 1.11
0.86
25.38
Price/Owner Earnings (ttm) 2.41
ENZN's Price/Owner Earnings (ttm) is ranked higher than
95% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. ENZN: 2.41 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ENZN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.32  Med: 4.17 Max: 1015
Current: 2.41
1.32
1015
P/B 0.90
ENZN's P/B is ranked higher than
93% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. ENZN: 0.90 )
Ranked among companies with meaningful P/B only.
ENZN' s P/B Range Over the Past 10 Years
Min: 0.88  Med: 2.20 Max: 13.28
Current: 0.9
0.88
13.28
P/S 1.14
ENZN's P/S is ranked higher than
94% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. ENZN: 1.14 )
Ranked among companies with meaningful P/S only.
ENZN' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 2.30 Max: 11.96
Current: 1.14
0.96
11.96
POCF 2.18
ENZN's POCF is ranked higher than
99% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. ENZN: 2.18 )
Ranked among companies with meaningful POCF only.
ENZN' s POCF Range Over the Past 10 Years
Min: 1.27  Med: 8.08 Max: 64.7
Current: 2.18
1.27
64.7
EV-to-EBIT 0.89
ENZN's EV-to-EBIT is ranked higher than
89% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. ENZN: 0.89 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZN' s EV-to-EBIT Range Over the Past 10 Years
Min: -292.6  Med: 0.90 Max: 137
Current: 0.89
-292.6
137
EV-to-EBITDA 0.89
ENZN's EV-to-EBITDA is ranked higher than
90% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. ENZN: 0.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.8  Med: 1.30 Max: 121.2
Current: 0.89
-76.8
121.2
Shiller P/E 0.79
ENZN's Shiller P/E is ranked higher than
91% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 56.77 vs. ENZN: 0.79 )
Ranked among companies with meaningful Shiller P/E only.
ENZN' s Shiller P/E Range Over the Past 10 Years
Min: 0.76  Med: 0.90 Max: 1.71
Current: 0.79
0.76
1.71
Current Ratio 38.20
ENZN's Current Ratio is ranked higher than
98% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ENZN: 38.20 )
Ranked among companies with meaningful Current Ratio only.
ENZN' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 5.81 Max: 49.77
Current: 38.2
1.06
49.77
Quick Ratio 38.20
ENZN's Quick Ratio is ranked higher than
98% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. ENZN: 38.20 )
Ranked among companies with meaningful Quick Ratio only.
ENZN' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 5.43 Max: 49.77
Current: 38.2
1.06
49.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.90
ENZN's Price/Net Cash is ranked higher than
86% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. ENZN: 1.90 )
Ranked among companies with meaningful Price/Net Cash only.
ENZN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.39  Med: 12.13 Max: 344
Current: 1.9
1.39
344
Price/Net Current Asset Value 1.82
ENZN's Price/Net Current Asset Value is ranked higher than
86% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. ENZN: 1.82 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.38  Med: 9.92 Max: 81.85
Current: 1.82
1.38
81.85
Price/Tangible Book 0.91
ENZN's Price/Tangible Book is ranked higher than
94% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ENZN: 0.91 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.06  Med: 6.23 Max: 412.5
Current: 0.91
1.06
412.5
Price/Median PS Value 0.49
ENZN's Price/Median PS Value is ranked higher than
84% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ENZN: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 1.94 Max: 62.26
Current: 0.49
0.57
62.26
Price/Graham Number 0.21
ENZN's Price/Graham Number is ranked higher than
99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. ENZN: 0.21 )
Ranked among companies with meaningful Price/Graham Number only.
ENZN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.25  Med: 1.14 Max: 13.98
Current: 0.21
0.25
13.98
Earnings Yield (Greenblatt) (%) 112.26
ENZN's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. ENZN: 112.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 15.20 Max: 401.6
Current: 112.26
0.7
401.6

More Statistics

Revenue (TTM) (Mil) $15.46
EPS (TTM) $ 0.36
Beta0.92
Short Percentage of Float0.41%
52-Week Range $0.39 - 1.56
Shares Outstanding (Mil)44.21
» More Articles for ENZN

Headlines

Articles On GuruFocus.com
Top Micro-Cap Picks From the Gurus Jun 23 2015 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
GuruFocus Real Time Picks of the Week Jan 10 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 
Billionaires Hold Bargains, 40% Off or More Sep 11 2013 
Charles Brandes Top Second Quarter Portfolio Changes Aug 09 2013 
First Pacific Advisors’ Top New Buys Aug 08 2012 
Enzon Inc. Reports Operating Results (10-K) Mar 16 2011 
Carl Icahn Buys NAV, CHK, ENZN, AMLN, CMC, Feb 15 2011 
Despite Bearish View, Seth Klarman Holds These Stocks: VSAT, THRX, NWSA, BBEP, ENZN, CSE Nov 25 2010 

More From Other Websites
ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jul 05 2016
Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 May 26 2016
ENZON PHARMACEUTICALS, INC. Financials May 25 2016
ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... May 16 2016
ENZON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 09 2016
Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: 2015 By the Numbers Mar 24 2016
ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Mar 21 2016
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 23 2016
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Feb 09 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Jan 27 2016
Enzon Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 10 2015
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 07 2015
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 03 2015
What Do Hedge Funds Think of Enzon Pharmaceuticals, Inc. (ENZN)? Nov 25 2015
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 12 2015
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 06 2015
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Sep 15 2015
Guidance & Quarterly Review on Four Biotech Companies Aug 14 2015
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)